Literature DB >> 28900036

Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.

Zhiguo Li1, Jinghui Liu1, Jie Li1, Yifan Kong1, George Sandusky2, Xi Rao3, Yunlong Liu3, Jun Wan3, Xiaoqi Liu4.   

Abstract

Polo-like kinase 1 (Plk1), a serine/threonine protein kinase normally expressed in mitosis, is frequently up-regulated in multiple types of human tumors regardless of the cell cycle stage. However, the causal relationship between Plk1 up-regulation and tumorigenesis is incompletely investigated. To this end, using a conditional expression system, here we generated Plk1 transgenic mouse lines to examine the role of Plk1 in tumorigenesis. Plk1 overexpression in mouse embryonic fibroblasts prepared from the transgenic mice led to aberrant mitosis followed by aneuploidy and apoptosis. Surprisingly, Plk1 overexpression had no apparent phenotypes in the mice. Given that no malignant tumor formation was observed even after a long period of Plk1 overexpression, we reasoned that additional factors are required for tumorigenesis in Plk1-overexpressing mice. Because Plk1 can directly participate in the regulation of the DNA damage response (DDR) pathway, we challenged Plk1-overexpressing mice with ionizing radiation (IR) and found that Plk1-overexpressing mice are much more sensitive to IR than their wild-type littermates. Analysis of tumor development in the Plk1-overexpressing mice indicated a marked decrease in the time required for tumor emergence after IR. At the molecular level, Plk1 overexpression led to reduced phosphorylation of the serine/threonine kinases ATM and Chk2 and of histone H2AX after IR treatment both in vivo and in vitro Furthermore, RNA-Seq analysis suggested that Plk1 elevation decreases the expression of several DDR genes. We conclude that Plk1 overexpression may contribute to tumor formation by both inducing chromosomal instability and suppressing the DDR pathway.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA damage response; DNA repair; cancer; cell cycle; mitosis; signal transduction

Mesh:

Substances:

Year:  2017        PMID: 28900036      PMCID: PMC5655521          DOI: 10.1074/jbc.M117.810960

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

Review 1.  Cell cycle kinases in cancer.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Curr Opin Genet Dev       Date:  2007-02       Impact factor: 5.578

Review 2.  Beyond ATM: the protein kinase landscape of the DNA damage response.

Authors:  Ariel Bensimon; Ruedi Aebersold; Yosef Shiloh
Journal:  FEBS Lett       Date:  2011-05-08       Impact factor: 4.124

3.  Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.

Authors:  Klaus Strebhardt; Sven Becker; Yves Matthess
Journal:  Expert Opin Drug Discov       Date:  2014-09-29       Impact factor: 6.098

4.  Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).

Authors:  Zhiguo Li; Ying Lu; Nihal Ahmad; Klaus Strebhardt; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

Authors:  X Shawn Liu; Hongchang Li; Bing Song; Xiaoqi Liu
Journal:  EMBO Rep       Date:  2010-06-25       Impact factor: 8.807

6.  Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.

Authors:  Troy A Baudino; Kirsteen H Maclean; Jennifer Brennan; Evan Parganas; Chunying Yang; Aaron Aslanian; Jacqueline A Lees; Charles J Sherr; Martine F Roussel; John L Cleveland
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

7.  Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells.

Authors:  Marcel A T M van Vugt; Alexandra Brás; René H Medema
Journal:  Mol Cell       Date:  2004-09-10       Impact factor: 17.970

8.  Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.

Authors:  Xianzeng Hou; Zhiguo Li; Weize Huang; Jiejie Li; Christopher Staiger; Shihuan Kuang; Tim Ratliff; Xiaoqi Liu
Journal:  Prostate       Date:  2013-05-09       Impact factor: 4.104

9.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

Review 10.  Polo-like kinase-1 in DNA damage response.

Authors:  Sun-Yi Hyun; Hyo-In Hwang; Hyo-In Hwan; Young-Joo Jang
Journal:  BMB Rep       Date:  2014-05       Impact factor: 4.778

View more
  8 in total

1.  Chk2-dependent phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) regulates centrosome maturation.

Authors:  Shanshan Nai; Yingxin Shi; Huanwei Ru; Yuehe Ding; Qizhi Geng; Zhe Li; Meng-Qiu Dong; Xingzhi Xu; Jing Li
Journal:  Cell Cycle       Date:  2019-08-15       Impact factor: 4.534

2.  Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin.

Authors:  Zhiguo Li; Yifan Kong; Longzhen Song; Qian Luo; Jinghui Liu; Chen Shao; Xianzeng Hou; Xiaoqi Liu
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

3.  PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.

Authors:  Lilia Gheghiani; Lei Wang; Youwei Zhang; Xavier T R Moore; Jinglei Zhang; Steven C Smith; Yijun Tian; Liang Wang; Kristi Turner; Colleen K Jackson-Cook; Nitai D Mukhopadhyay; Zheng Fu
Journal:  Cancer Res       Date:  2020-12-29       Impact factor: 13.312

4.  Plk1 overexpression induces chromosomal instability and suppresses tumor development.

Authors:  Guillermo de Cárcer; Sharavan Vishaan Venkateswaran; Lorena Salgueiro; Aicha El Bakkali; Kalman Somogyi; Konstantina Rowald; Pablo Montañés; Manuel Sanclemente; Beatriz Escobar; Alba de Martino; Nicholas McGranahan; Marcos Malumbres; Rocío Sotillo
Journal:  Nat Commun       Date:  2018-08-01       Impact factor: 14.919

Review 5.  The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?

Authors:  Guillermo de Cárcer
Journal:  Genes (Basel)       Date:  2019-03-11       Impact factor: 4.096

6.  A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.

Authors:  Mengjiao Wu; Yan Wang; Di Yang; Ying Gong; Feng Rao; Rui Liu; Yeerken Danna; Jinting Li; Jiawen Fan; Jie Chen; Weimin Zhang; Qimin Zhan
Journal:  EBioMedicine       Date:  2019-03-12       Impact factor: 8.143

7.  Expression-based analyses indicate a central role for hypoxia in driving tumor plasticity through microenvironment remodeling and chromosomal instability.

Authors:  Anqi Jing; Frederick S Vizeacoumar; Sreejit Parameswaran; Bjorn Haave; Chelsea E Cunningham; Yuliang Wu; Roland Arnold; Keith Bonham; Andrew Freywald; Jie Han; Franco J Vizeacoumar
Journal:  NPJ Syst Biol Appl       Date:  2018-10-24

Review 8.  The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.

Authors:  Cordell VanGenderen; Troy Anthony Alan Harkness; Terra Gayle Arnason
Journal:  Aging (Albany NY)       Date:  2020-08-15       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.